The dawn of mRNA vaccines: The COVID-19 case

In less than one year since the outbreak of the COVID-19 pandemic, two mRNA-based vaccines, BNT162b2 and mRNA-1273, were granted the first historic authorization for emergency use, while another mRNA vaccine, CVnCoV, progressed to phase 3 clinical testing. The COVID-19 mRNA vaccines represent a new...

Descripción completa

Detalles Bibliográficos
Autores principales: Verbeke, Rein, Lentacker, Ine, De Smedt, Stefaan C., Dewitte, Heleen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8008785/
https://www.ncbi.nlm.nih.gov/pubmed/33798667
http://dx.doi.org/10.1016/j.jconrel.2021.03.043

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8008785/
https://www.ncbi.nlm.nih.gov/pubmed/33798667
http://dx.doi.org/10.1016/j.jconrel.2021.03.043

Ejemplares similares